The invention constructs an activating KRASmutant but not p53-responsive promoter and generates an E1B-55kD-deleted (ΔE1B-55kD) adenovirus, harboring a transcriptionally activating transgene and holding lytic replication ability in the tumor cells with activating KRASmutant. The adenovirus of the invention can be used in the treatment of cancers.